FrancophonIA/ELRC3.0 huggingface dataset:
English: Tepadina is used with other medicines before transplantation to destroy the abnormal cells and the patient's existing blood-making cells.
Slovenian: Zdravilo Tepadina se uporablja z drugimi zdravili pred presaditvijo za uničenje nenormalnih celic in bolnikovih obstoječih krvotvornih celic.
English: The Committee decided that, based on available published information, Tepadina's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor je na podlagi razpoložljivih objavljenih podatkov zaključil, da so koristi zdravila Tepadina večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tepadina.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: The active substance in Tepadina, thiotepa, belongs to a group of medicines called ‘alkylating agents'.
Slovenian: Zdravilna učinkovina zdravila Tepadina, tiotepa, spada v skupino zdravil, imenovanih „alkilirajoča sredstva“.
English: Tepadina can be used for transplantation of cells from a donor and for transplantation of cells derived from the patient's own body.
Slovenian: Zdravilo Tepadina se lahko uporablja za presaditev darovalčevih celic in za presaditev celic, ki izvirajo iz telesa bolnika samega.
English: The dose also depends on the patient's body surface area (calculated using the height and weight of the patient) or on the patient's weight.
Slovenian: Odvisen je tudi od telesne površine bolnika (izračunane glede na telesno višino in maso bolnika) ali od njegove telesne mase.
English: For more information about treatment with Tepadina, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist..
Slovenian: Za več informacij o zdravljenju z zdravilom Tepadina preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali s farmacevtom.
English: • during the treatment of solid tumours when high-dose chemotherapy followed by transplantation of haematopoietic progenitor cells is needed.
Slovenian: • med zdravljenjem čvrstih tumorjev, ko je potrebna kemoterapija z visokimi odmerki, kateri sledi presaditev krvotvornih matičnih celic.
English: The most common side effects seen with Tepadina when used with other medicines are infections, cytopenia (low number of cells in the blood), graft-versus-host disease (when the transplanted cells attack the body), disorders of the gut, haemorrhagic cystitis (bleeding and inflammation in the bladder) and mucosal inflammation (inflammation of the moist body surfaces).
Slovenian: Najpogostejši neželeni učinki zdravila Tepadina v kombinaciji z drugimi zdravili so okužbe, citopenija (nizko število celic v krvi), reakcija presadka proti gostitelju (ko presajene celice napadejo telo), črevesne bolezni, hemoragični cistitis (krvavitve in vnetje mehurja) in vnetje sluznice (vnetje vlažnih telesnih površin).
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tepadina, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti tega zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: For the full list of all side effects reported with Tepadina in adults and children, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Tepadina pri odraslih in otrocih, glejte navodilo za uporabo.
English: The published studies showed that thiotepa used in combination with other chemotherapy medicines is beneficial to adults and children being treated for blood diseases and solid tumours.
Slovenian: Iz objavljenih študij je razvidno, da ima zdravilna učinkovina tiotepa, če se uporablja v kombinaciji z drugimi kemoterapevtiki, koristne učinke pri odraslih in otrocih, ki se zdravijo zaradi krvnih bolezni in čvrstih tumorjev.
English: Tepadina must not be used in women who are pregnant or breast-feeding.
Slovenian: Zdravila Tepadina ne smejo uporabljati nosečnice ali doječe matere.
English: Why has Tepadina been approved?
Slovenian: Zakaj je bilo zdravilo Tepadina odobreno?
English: The CHMP noted that the active substance in Tepadina, thiotepa, has a well established used.
Slovenian: CHMP je zaključil, da je uporaba zdravilne učinkovine zdravila Tepadina, tiotepa, dobro uveljavljena.
English: It contains the active substance thiotepa.
Slovenian: Vsebuje zdravilno učinkovino tiotepa.
English: Tepadina is a powder that is made up into a solution for infusion (drip into a vein).
Slovenian: Zdravilo Tepadina je prašek za pripravo raztopine za infundiranje (kapalne infuzije v veno).
English: What is Tepadina used for?
Slovenian: Za kaj se zdravilo Tepadina uporablja?
English: This type of transplant is used in patients who need to replace their blood-making cells because they have a blood disease such as a cancer of the blood
Slovenian: Ta vrsta presaditve se uporablja pri bolnikih, pri katerih je treba zamenjati krvotvorne celice, ker imajo krvno bolezen, kot je krvni rak (vključno z levkemijo), ali bolezen, ki povzroča nizko raven rdečih krvničk (vključno s talasemijo ali anemijo srpastih celic);
English: How has Tepadina been studied?
Slovenian: Kako je bilo zdravilo Tepadina raziskano?
English: How is Tepadina used?
Slovenian: Kako se zdravilo Tepadina uporablja?
English: What is Tepadina?
Slovenian: Kaj je zdravilo Tepadina?
English: How does Tepadina work?
Slovenian: Kako zdravilo Tepadina deluje?
English: The full EPAR for Temozolomide Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Temozolomide Sandoz je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European Public Assessment Report (EPAR) for Temozolomide Sandoz.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Temozolomide Sandoz.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Temozolomide Sandoz on 15 March 2010.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Temozolomide Sandoz, veljavno po vsej Evropski uniji, izdala 15. marca 2010.
English: For more information about treatment with Temozolomide Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Temozolomide Sandoz preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: This means that Temozolomide Sandoz is similar to a ‘reference medicine' already authorised in the European Union (EU) called Temodal.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Temodal.
English: Because Temozolomide Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Temozolomide Sandoz generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: Temozolomide Sandoz should be taken without food.
Slovenian: Zdravilo Temozolomide Sandoz je treba jemati brez hrane.
English: Temozolomide Sandoz is used first with radiotherapy and then on its own;
Slovenian: Zdravilo Temozolomide Sandoz se najprej uporabi skupaj z radioterapijo, nato pa samostojno;
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Sandoz.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Treatment with Temozolomide Sandoz should be prescribed by a doctor with experience in the treatment of brain tumours.
Slovenian: Zdravljenje z zdravilom Temozolomide Sandoz mora predpisati zdravnik, ki ima izkušnje z zdravljenjem možganskih tumorjev.
English: The CHMP concluded that, in accordance with EU requirements, Temozolomide Sandoz has been shown to have comparable quality and to be bioequivalent to Temodal.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Temozolomide Sandoz primerljivo raven kakovosti kot zdravilo Temodal ter da mu je biološko enakovredno.
English: The Committee recommended that Temozolomide Sandoz be given marketing authorisation.
Slovenian: Odbor je priporočil, da se za zdravilo Temozolomide Sandoz odobri dovoljenje za promet.
English: Because Temozolomide Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal.
Slovenian: Ker je zdravilo Temozolomide Sandoz generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Temodal.
English: Temozolomide Sandoz is a ‘generic medicine'.
Slovenian: Temozolomide Sandoz je „generično zdravilo“.
English: What are the benefit and risk of Temozolomide Sandoz?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Temozolomide Sandoz?
English: Other information about Temozolomide Sandoz
Slovenian: Druge informacije o zdravilu Temozolomide Sandoz
English: Temozolomide Sandoz temozolomide
Slovenian: Temozolomide Sandoz temozolomid
English: The active substance in Temozolomide Sandoz, temozolomide, belongs to a group of anticancer medicines called alkylating agents.
Slovenian: Zdravilna učinkovina zdravila Temozolomide Sandoz, temozolomid, spada v skupino zdravil proti raku, imenovanih alkilirajoči citostatiki.
English: The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Sandoz is being used alone or with other treatments, and how the patient responds to treatment.
Slovenian: Odmerek zdravila Temozolomide Sandoz je odvisen od telesne površine (izračunane glede na telesno višino in maso bolnika) in sega od 75 do 200 mg na kvadratni meter, enkrat na dan. Odmerek in število odmerkov sta odvisna od vrste zdravljenega tumorja ter od tega, ali je bil bolnik že zdravljen, ali se zdravilo Temozolomide Sandoz uporablja samostojno ali skupaj z drugimi zdravljenji in kako se bolnik odziva na zdravljenje.
English: Temozolomide Sandoz is an anticancer medicine.
Slovenian: Temozolomide Sandoz je zdravilo proti raku.
English: Temozolomide Sandoz is a medicine that contains the active substance temozolomide.
Slovenian: Temozolomide Sandoz je zdravilo, ki vsebuje zdravilno učinkovino temozolomid.
English: Why has Temozolomide Sandoz been approved?
Slovenian: Zakaj je bilo zdravilo Temozolomide Sandoz odobreno?
English: Temozolomide Sandoz is used on its own in these patients.
Slovenian: Pri teh bolnikih se zdravilo Temozolomide Sandoz uporablja samostojno.
English: Patients may also need to take medicines to prevent vomiting before taking Temozolomide Sandoz.
Slovenian: Preden bo bolnik vzel zdravilo Temozolomide Sandoz, bo morda potreboval tudi zdravilo za preprečevanje bruhanja.
English: What is Temozolomide Sandoz?
Slovenian: Kaj je zdravilo Temozolomide Sandoz?
English: How has Temozolomide Sandoz been studied?
Slovenian: Kako je bilo zdravilo Temozolomide Sandoz raziskano?
English: What is Temozolomide Sandoz used for?
Slovenian: Za kaj se zdravilo Temozolomide Sandoz uporablja?
English: How is Temozolomide Sandoz used?
Slovenian: Kako se zdravilo Temozolomide Sandoz uporablja?
English: How does Temozolomide Sandoz work?
Slovenian: Kako zdravilo Temozolomide Sandoz deluje?
English: Tell your doctor:
Slovenian: Povejte svojemu zdravniku:
English: About one in five patients suffered from these feelings.
Slovenian: Takšne občutke je občutil približno eden izmed petih bolnikov.
English: Elderly patients (> 65 years old)
Slovenian: Starejši bolniki (> 65 let)
English: • difficulty in sleeping
Slovenian: • težave s spanjem,
English: • if you have or have had any heart problems.
Slovenian: • če imate ali ste kadarkoli imeli težave s srcem,
English: The clinical relevance of these findings is not known.
Slovenian: Klinična pomembnost teh ugotovitev ni znana.
English: Ideal body weight can be determined using the following equations:
Slovenian: Idealno telesno maso lahko določite z uporabo naslednjih enačb:
English: Appropriate precautions should be taken because of the potential for these reactions.
Slovenian: Upoštevati je treba ustrezne varnostne ukrepe zaradi možnosti pojava navedenih reakcij.
English: In a few cases, enough stem cells may not be collected, and the collection attempt will be stopped.
Slovenian: V redkih primerih se zgodi, da ni mogoče zbrati dovolj matičnih celic, in bo poskus zbiranja ustavljen.
English: From a microbiological point of view the product should be used immediately.
Slovenian: Iz mikrobiološkega vidika morate zdravilo uporabiti takoj.
English: Please tell your doctor immediately if
Slovenian: Nemudoma obvestite svojega zdravnika, če
English: * The frequency of allergic reactions presented is based on adverse reactions that occurred in the oncology studies (679 patients).
Slovenian: * Pogostost prikazanih alergijskih reakcij temelji na neželenih učinkih, ki so bili ugotovljeni v onkoloških študijah (679 bolnikov).
English: However, these effects do not seem to occur more frequently when you use Mozobil.
Slovenian: Vendar se zdi, da se navedena učinka nista pojavila bolj pogosto ob uporabi zdravila Mozobil.
English: The safety profile in this paediatric study was consistent with what has been observed in adults.
Slovenian: Varnostni profil v tej pediatrični študiji je bil skladen s tem, kar so opazili pri odraslih.
English: It is important to tell your doctor if you are, think you may be or are planning to become pregnant.
Slovenian: Pomembno je, da obvestite svojega zdravnika, če ste noseči, če mislite, da ste morda noseči, ali če načrtujete, da bi zanosili.
English: The elimination rate from tissues was slow.
Slovenian: Stopnja izločanja iz tkiv je bila počasna.
English: • low red blood cell count by laboratory test (anaemia in children)
Slovenian: • nizko število rdečih krvnih celic ugotovljeno z laboratorijskim testom (anemija pri otrocih))
English: If you have moderate or severe kidney problems, your doctor will reduce the dose.
Slovenian: Če imate zmerne ali resne težave z ledvicami, bo zdravnik znižal odmerek.
English: Studies in animals have shown teratogenicity (see section 5.3).
Slovenian: Študije na živalih so pokazale teratogenost (glejte poglavje 5.3).
English: Clinical data with this dose adjustment are limited.
Slovenian: Klinični podatki tako prilagojenega odmerka so omejeni.
English: Your medicine will be injected by a doctor or a nurse.
Slovenian: Zdravilo bo injiciral zdravnik ali medicinska sestra.
English: It is recommended to use contraception if you are of child-bearing age.
Slovenian: Priporočamo, da uporabljate kontracepcijo, če ste v rodni dobi.
English: Treatment lasts 2 to 4 consecutive days (in some cases up to 7 days), until enough stem cells have been collected for your transplant.
Slovenian: Zdravljenje traja od 2 do 4 zaporedne dni (v nekaterih primerih do 7 dni), dokler se ne zbere dovolj matičnih celic za vašo presaditev.
English: Date of first authorisation: 31 July 2009 Date of latest renewal: 11 April 2014
Slovenian: Datum zadnjega podaljšanja: 11. april 2014
English: The potential risk associated with this effect is expected to be low for the intended short term duration of dosing plerixafor in humans.
Slovenian: Pričakovati je, da bo možno tveganje, povezano z navedenim vplivom, nizko zaradi predvidenega kratkoročnega dajanja pleriksaforja pri ljudeh.
English: Each vial is intended for single use only.
Slovenian: Vsaka viala zdravila Mozobil je namenjena samo enkratni uporabi.
English: Your doctor may perform regular blood tests to monitor your blood cell count.
Slovenian: Vaš zdravnik bo morda izvajal redne krvne teste za spremljanje števila krvnih celic.
English: The elimination half-life (t1/2) in plasma is 3-5 hours.
Slovenian: Razpolovni čas (t1/2) izločanja v plazmi je od 3 do 5 ur.
English: Plerixafor is moderately bound to human plasma proteins up to 58%.
Slovenian: Pleriksafor se zmerno veže na proteine v človeški plazmi do 58 %.
English: female (kg):
Slovenian: ženske (kg):
English: What you need to know before you use Mozobil
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo Mozobil
English: Please inform your doctor immediately if you experience chest discomfort.
Slovenian: Prosimo, da nemudoma obvestite svojega zdravnika, če začutite neugodje v prsih.
English: Frequencies are defined according to the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
Slovenian: Navedba pogostosti neželenih učinkov je opredeljena, kot sledi: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
Slovenian: Če ga ne uporabite takoj, uporabnik prevzame odgovornost za čas in pogoje shranjevanja pred uporabo.
English: Therefore, you should avoid driving if you feel dizzy, tired or unwell.
Slovenian: Zato ne vozite avtomobila, če čutite omotico, utrujenost ali se ne počutite dobro.
English: Plerixafor is rapidly absorbed following subcutaneous injection, reaching peak concentrations in approximately 30-60 minutes (tmax).
Slovenian: Pleriksafor se hitro absorbira po subkutanem injiciranju in doseže najvišje koncentracije v približno 30-60 minutah (tmax).
English: This teratogenic potential is likely due to its pharmacodynamic mechanism of action.
Slovenian: Navedeni teratogeni potencial verjetno izhaja iz farmakodinamičnega mehanizma delovanja.
English: Women of childbearing potential Women of childbearing potential have to use effective contraception during treatment.
Slovenian: Ženske v rodni dobi Ženske v rodni dobi morajo med zdravljenjem uporabljati učinkovito kontracepcijo.
English: Some patients have experienced dizziness, fatigue or vasovagal reactions; therefore caution is advised when driving or operating machines.
Slovenian: Pri nekaterih bolnikih so se pojavile omotica, utrujenost ali vazovagalne reakcije, zatorej se priporoča previdnost pri vožnji ali upravljanju s stroji.
English: If you want to know more about G-CSF ask your doctor and read the corresponding package leaflet.
Slovenian: Če želite izvedeti več o zdravilu G-CSF, vprašajte svojega zdravnika in preberite navodilo za uporabo zdravila G-CSF.
English: Fertility The effects of plerixafor on male and female fertility are not known (see section 5.3).
Slovenian: Plodnost Učinki pleriksaforja na plodnost pri moških in ženskah niso znani (glejte poglavje 5.3).
English: In the two placebo-controlled clinical studies of plerixafor, 24% of patients were ≥ 65 years old.
Slovenian: V dveh s placebom kontroliranih študijah s pleriksaforjem je bilo 24 % bolnikov starih ≥ 65 let.
English: G-CSF will help Mozobil to work properly in your body.
Slovenian: G-CSF pomaga zdravilu Mozobil pri pravilnem delovanju v vašem telesu.
English: ** From post-marketing experience
Slovenian: ** Izkušnje v obdobju trženja zdravila.
English: Pharmacotherapeutic group: Other immunostimulants; ATC code: L03AX16
Slovenian: Farmakoterapevtska skupina: druga zdravila za spodbujanje imunske odzivnosti, oznaka ATC: L03AX16
English: You will first receive G-CSF, then you will be given Mozobil Mobilisation will be started by first giving you another medicine called G-CSF (granulocyte-colony stimulating factor).
Slovenian: Najprej boste prejeli G-CSF ter nato zdravilo Mozobil Na začetku mobilizacije boste najprej prejeli drugo zdravilo z imenom G-CSF (granulocitne kolonije stimulirajoči faktor).
English: Plerixafor dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated.
Slovenian: Odmerjanja zdravila pleriksafor in zdravljenja bolnikov z več kot 175 % idealne telesne mase niso raziskali.
English: male (kg):
Slovenian: moški (kg):
English: When is Mozobil given for the first time?
Slovenian: Kdaj boste prvič prejeli zdravilo Mozobil?
English: • abnormal dreams, nightmares
Slovenian: • nenormalne sanje, nočne more
English: Your dose will depend on your body weight, which should be measured the week before you receive your first dose.
Slovenian: Odmerek zdravila je odvisen od vaše telesne mase, ki bo izmerjena teden pred prvim odmerkom.
English: Renal impairment had no effect on Cmax..
Slovenian: Okvara ledvic ni imela nobenega vpliva na vrednost Cmax.
English: You will receive your first dose 6 to 11 hours before apheresis (collection of your blood stem cells).
Slovenian: Prvi odmerek zdravila boste prejeli od 6 do 11 ur pred aferezo (zbiranjem vaših krvnih matičnih celic).
English: Rescue patients
Slovenian: Reševani bolniki
English: The safety and efficacy of Mozobil in children (1 to less than 18 years) were studied in an open label, multicenter, controlled study (see sections 4.8, 5.1, and 5.2).
Slovenian: Varnost in učinkovitost zdravila Mozobil pri otrocih (od 1 do manj kot 18 let) je bila raziskana v odprti, multicentrični, kontrolirani študiji (glejte poglavja 4.8, 5.1, in 5.2).
English: Events included one or more of the following: urticaria (n = 2), periorbital swelling (n = 2), dyspnoea (n = 1) or hypoxia (n = 1).
Slovenian: Vključno z enim ali več od naslednjih neželenih učinkov: urtikarija (n = 2), periorbitalno zatekanje (n = 2), dispneja (n = 1) ali hipoksija (n = 1).
English: No complications or clinical symptoms of leukostasis were observed.
Slovenian: Zapletov ali kliničnih simptomov levkostaze niso opazili.
English: The pharmacist will throw away medicines you no longer use.
Slovenian: Zdravilo, ki ga ne uporabljate več, bo odvrgel farmacevt.
English: The majority of these events occurred within 1 hour of Mozobil administration.
Slovenian: Večina navedenih dogodkov se je pojavila v 1 uri po prejetju zdravila Mozobil.
English: Mozobil should not be used during pregnancy unless the clinical condition of the woman requires treatment with plerixafor.
Slovenian: Zdravila Mozobil ne uporabljajte med nosečnostjo, razen če klinično stanje bolnice zahteva zdravljenje s pleriksaforjem.
English: From chemotherapy/ablative treatment in preparation of transplantation through 12 months post-transplantation, no significant differences in the incidence of adverse reactions were observed across treatment groups.
Slovenian: V razdobju od kemoterapije/ablativnega zdravljenja kot priprave za presaditev do konca 12. meseca po presaditvi niso opazili znatnih razlik v pojavnosti neželenih učinkov pri vseh skupinah zdravljenja.
English: • In children age 1 to less than 18 years of age with lymphoma or solid tumours.
Slovenian: • pri otrocih, starih od 1 do manj kot 18 let, z limfomom ali parenhimskimi tumorji.
English: Breast-feeding should be discontinued during treatment with Mozobil.
Slovenian: Dojenje je treba prekiniti med zdravljenjem z zdravilom Mozobil.